Abstract
Theiler’s murine encephalomyelitis virus (TMEV) establishes persistent viral infections in the central nervous system and induces chronic inflammatory demyelinating disease in susceptible mice. TMEV infects dendritic cells, macrophages, B cells, and glial cells. The state of TLR activation in the host plays a critical role in initial viral replication and persistence. The further activation of TLRs enhances viral replication and persistence, leading to the pathogenicity of TMEV-induced demyelinating disease. Various cytokines are produced via TLRs, and MDA-5 signals linked with NF-κB activation following TMEV infection. In turn, these signals further amplify TMEV replication and the persistence of virus-infected cells. The signals further elevate cytokine production, promoting the development of Th17 responses and preventing cellular apoptosis, which enables viral persistence. Excessive levels of cytokines, particularly IL-6 and IL-1β, facilitate the generation of pathogenic Th17 immune responses to viral antigens and autoantigens, leading to TMEV-induced demyelinating disease. These cytokines, together with TLR2 may prematurely generate functionally deficient CD25-FoxP3+ CD4+ T cells, which are subsequently converted to Th17 cells. Furthermore, IL-6 and IL-17 synergistically inhibit the apoptosis of virus-infected cells and the cytolytic function of CD8+ T lymphocytes, prolonging the survival of virus-infected cells. The inhibition of apoptosis leads to the persistent activation of NF-κB and TLRs, which continuously provides an environment of excessive cytokines and consequently promotes autoimmune responses. Persistent or repeated infections of other viruses such as COVID-19 may result in similar continuous TLR activation and cytokine production, leading to autoimmune diseases.
1 Theiler’s virus
Theiler’s murine encephalomyelitis virus (TMEV) belongs to the family of picornavirus, possessing a single positive RNA genome (1, 2). The picornavirus family includes a wide range of human pathogens, including rhinoviruses, cardioviruses, enteroviruses, and aphthoviruses, and TMEV belongings to the cardioviral group (3, 4). Two major subgroups of TMEV have been identified. One subgroup including GDVII and FA viruses, causes rapid and fatal encephalitis. Another subgroup including the BeAn8386 and DA strains, is known as Theiler’s original (TO) viruses. The inoculation of TO viruses intracerebrally into susceptible mice results in a biphasic neurological disease (2, 5–9). The early, acute phase displays flaccid limb paralysis and the degeneration of neurons (poliomyelitis). The late phase exhibits chronic, inflammatory demyelination (2). In contrast to the DA strain, the BeAn strain of the TO virus group is known to induce a clinically undetectable early-phase disease, although it results in a severe late-phase demyelinating disease (8, 9).
Viruses such as TMEV have been associated with CNS diseases including multiple sclerosis (10–14). Multiple sclerosis (MS) is a long-lasting autoimmune-mediated disease, resulting in demyelination in the white matter of the central nervous system (15). To understand the underlying pathogenic mechanisms of MS, several virus-induced models have been investigated (5, 7, 16, 17). Among virus-induced models, TMEV-induced demyelinating disease in mice has been extensively investigated because of the similarities in its histopathologic characteristics (2, 5, 18, 19). In addition, Saffold virus is an emerging human Theiler’s virus group, infecting more than 90% of human populations, which implicates potential importance in public health (20–22). MS may therefore involve chronic viral infections associated with the development of pathogenic immune responses reactive to viral and/or self-antigens. To explain virus-induced demyelinating disease in mice, several hypotheses have been proposed. First, “bystander” damage to CNS tissues occurs because of the host immune response against viral determinants (23, 24). Second, autoimmune responses to myelin proteins from damages to the CNS by anti-viral immune responses cause the disease development (19, 25, 26). Third, CNS damage incurred by persistent antiviral and autoimmune responses are induced by chronic over-stimulation via TLRs and other pathogen pattern recognition receptors (19, 27). Defining the underlying pathogenic mechanisms associated with TLR engagement with well-defined disease system like TMEV-induced demyelination has paramount importance in understanding the role of TLRs on viral persistence, cytokine production, and development of pathogenic immune responses, including autoimmune responses.
Infection with TMEV causes demyelinating disease only in certain mouse strains. C57BL/6 (B6) mice represent a resistant strain and SJL/J (SJL) mice represent a susceptible strain (28, 29). The viral loads in the spinal cords of resistant C57BL/6 mice are significantly lower than those of susceptible SJL mice throughout the viral infection period (30). Various cell types are permissive to TMEV infection, and these include oligodendrocytes, microglia, and astrocytes in the CNS and the dendritic cells, macrophages, and B cells in the CNS and periphery (31–35). The major cell populations that support viral persistence during chronic TMEV infection are microglia and/or macrophages in the CNS (36–39). Viral replication in microglia from susceptible SJL mice is significantly higher than that in microglia from resistant C57BL/6 mice and the viral load is similarly greater in microglia from SJL mice infected with TMEV compared with microglia from C57BL/6 mice (39). Because TMEV persistence in the CNS is a critically important prerequisite in the pathogenesis of demyelination (30, 40, 41), viral persistence may lead to continuous inflammatory cytokine production and the consequent pathogenic immune responses in the development of TMEV-induced demyelinating disease (Figure 1).
Figure 1
(1) 1-3 d post-infection: initial viral infection; (2) 4-8 d post-infection: early viral infection; (3) 9-30 d post-infection; (4) 31-80 d post-infection: chronic viral persistence. Resistant mice such as B6 and B6.S mice show rapid clearance of virus within 2-3 weeks, whereas susceptible SJL mice fail to clear viral persistence. Consequently, persistent TLR activation throughout infection leads to elevated levels of cytokines such as type I IFNs, IL-6, and IL-1beta, which favors stimulation of pathogenic Th17 response over protective Th1 response. Such pathogenic immune responses lead to the development of demyelinating disease in TMEV-infected SJL mice.
2 TLR expression and activation status may determine the susceptibility to viral infection
Toll-like receptors (TLRs) include a family of members, which recognize microbial products. This family of receptors is known to closely associate with the induction of initial innate immune responses following bacterial and viral infections (42, 43). mRNAs for TLR1–9 are expressed in microglia and stimulation of TLRs on the cells upregulates the expression of MHC class II and costimulatory molecules, which enable the microglia to present antigens to CD4+ T cells (38). Activated and/or differentiated cells are far more supportive of TMEV infection/replication (44–46). Consequently, the cytokine production levels in APCs, including microglia, in susceptible SJL mice are higher than those in resistant B6 mice (30, 39). For example, higher levels of TNFα, IL-6 and IL-1β are produced in microglia and macrophages from susceptible SJL mice after TMEV infection, compared with cells from resistant B6, B6.S, or B10.S mice (47–49). Similarly, viral loads in glia and antigen-presenting cells (APCs) from susceptible SJL mice with TMEV-induced demyelinating disease are significantly greater than that in cells from resistant B6.S, B6, and F1(B6XSJL) mice (34, 39). However, the levels of costimulatory molecule expression on APCs from susceptible mice and their ability to stimulate T cells during chronic TMEV infection are significantly poorer, which steers the pathogenic T cell responses (34, 39). Elevated TLR2, 3, 4, and 7 signaling in APCs enhances viral infection and replication (39, 50). Thus, persistent viral infection accompanied by continuous excessive cytokine production leads to viral persistence and the development of pathogenic immune responses. The association of TLR signals with pathogenesis is further supported by the fact that the administration of bacterial lipopolysaccharide (LPS), a ligand for TLR4, or poly I:C, a ligand for TLR3, increases viral loads and elevates the level of inflammatory response (50, 51). Thus, the differences in the type and intensity of TLR signals on antigen-presenting cells may affect the levels of viral infection, replication, and production of IL-1β and IL-6, which are critical factors in the development of demyelinating disease (Figure 2A).
Figure 2
(A) TMEV infection releases a single-stranded RNA genome and double-stranded RNA replication intermediate in the endosome. The single-stranded RNA is recognized by TLR7 and the dsRNA intermediate is recognized by TLR3. The TLR signaling activates NF-κB, AP-1, and IRFs, which results in the production of various cytokines such as IL-6, IL-1beta, and type I IFNs. In addition, MDA5 also recognizes dsRNA replication intermediate, leading to NF-κB activation. These activations lead to the additional expression of TLR2/4 and other TLRs which further participates in activating NF-κB. The amplified NF-κB signaling further promotes TMEV replication because TMEV replication is dependent on the presence of activated NF-κB. (B) TLR signaling activates NF-κB, which results in the production of anti-apoptotic MCL-1, Bcl-2, Bcl-xL, and IL-6, inhibiting apoptosis induced by cytotoxic T cells and IFNs. IL-6 and IL-1beta further promote the generation of pathogenic Th17 cells. IL-17 produced by Th17 cells together with IL-6 synergistically inhibit the apoptosis of virus-infected cells by activating NF-κB and STAT3, leading to production of additional anti-apoptotic molecules in the mitochondria. The prolonged various TLR signals leading to NF-κB activation participate in the prolonged production of anti-apoptotic molecules and continuous TMEV replication.
3 NF-κB activation via TLRs is necessary for TMEV replication and cytokine production
TMEV has a single RNA genome which is recognized by TLR7, and a dsRNA intermediate which is recognized by TLR3 (42, 43). Consequently, TMEV infection leads to activation of NF-κB, AP-1, and IRFs via the TLR signals, resulting in the production of various cytokines, including IL-1β and IL-6 (39, 52–54). The melanoma differentiation-associated gene 5 also recognizes viral messages and participates in the activation of NF-κB (55). The infection of primary glial cells results in the activation of a wide range of chemokine genes, including CXCL1, CXCL2, CXCL10, CCL2, CCL3, CCL4, CCL5, CCL7 and CCL12 (56–58). The production of chemokines and cytokines following various viral infections is dependent on the activation of NF-κB via pattern recognition receptors (32, 52, 59–62). These chemokines further activate CXCR3, CCR7 and CCR5 genes, which further promote the cellular recruitment and infiltration to the CNS (63, 64). In addition, IL-1β, IL-6, IFNα/β, and TNFα produced following TMEV infection further stimulate cells and upregulate the production of CCL2, CCL5, CXCL10 (65–67). These cytokines further promote the development of pathogenic Th17 cells and consequent demyelination (27, 34, 39, 68). Increases in the production of fibrin deposition, adhesion molecules (ICAM and VCAM), and endothelin-1 associated with blood–brain-barrier permeability, contributing to the pathogenesis of demyelinating disease have also been observed after TMEV infection (35, 69–72).
The treatment of resistant C57BL/6 mice with LPS, a ligand of TLR4, or IL-1β increases the viral load in the CNS and leads to the pathogenesis of demyelinating disease (51, 73). Similarly, administration of poly I:C, a ligand of TLR3 leads to the rapid progression of demyelinating disease in mice infected with TMEV (50). The activation of NF-κB via TLRs is associated with TMEV replication and the production of various inflammatory cytokines and chemokine (52, 66, 67). Furthermore, TNF-α, IL-6, and IL-1β produced after TMEV infection further activate NF-κB, promoting increased TMEV replication. NF-κB activation further leads to stimulation of additional TLRs, amplifying pathogenic signals in the deployment of demyelinating disease (45, 52, 66, 74, 75). This is consistent with the fact that TMEV infection and replication are greater in the cells of susceptible mice and that excessive TLR signal and cytokine production, including IL-1β, IL-6, and TGFβ, further promotes the pathogenesis of demyelinating disease (47, 52, 66).
TMEV infection also activates NLRP3 via TLR signaling (74). Activation of NLRP3 inflammasome results in the production of IL-1β and PEG2, promoting the pathogenesis (75, 76). TMEV-infected susceptible SJL mice produce much greater levels of IL-1β and other inflammatory cytokines compared with resistant mice. The presence of high levels of IL-1β and other inflammatory cytokines such as IL-6 promotes pathogenic Th17 responses (47, 68, 73). In addition, IL-17 from Th17 responses further promotes IL-6 production (77, 78), together inhibiting cellular apoptosis (68, 79). The excessive activation of PGE2 signaling also contributes to pathogenesis (74, 80) by preventing the T cell killing of target cells (81). TMEV infection also results in the increased expression of PD-1 and PDL-1 via IL-6 signaling, inhibiting cytotoxic T cell function (81, 82). Moreover, the IL-1β signal induces IL-6 production and further promotes Th17 cell expansion (73, 83). Thus, elevated perpetual TLR signaling and consequent persistent cytokine overproduction lead to viral persistence by blocking apoptosis and consequently facilitate pathogenic immune responses in susceptible mice infected with TMEV.
4 Excessive cytokine production via TLR activation leads to pathogenic immune responses
TMEV-specific Th1 cells producing IFN-γ can lyse virus-infected cells in a Fas-dependent manner (84). The presence of capsid specific Th1 responses delays the development of demyelinating disease (85–87). In addition, mice deficient in IFN-γ or its receptor genes cannot efficiently clear TMEV infection, resulting in rapid development of demyelinating disease (88, 89). Similarly, deficiency in the IFN-γ receptor significantly accelerates the onset of disease in mice (90, 91). Thus, the level of Th1 responses may play a protective role in the development of TMEV-induced demyelinating disease.
Th17 cells, a subpopulation of Th cells which produce IL-17, are associated with the development of various autoimmune diseases (92–95). Th17 cells are developed in the presence of IL-6, and Th17 cell levels are significantly greater in susceptible mice infected with TMEV. The role of Th17 responses in the pathogenesis of TMEV-induced demyelinating disease has been verified by administrating anti-IL-17 antibodies (68) or using Th17-biased RORγt Tg mice (96). DCs infected with live TMEV producing various innate immune responses, but not epitope peptide-loaded DCs, are able to induce the development of Th17 responses (68). These results indicate that the virus-infected environment, including the presence of various cytokines, is required to induce pathogenic Th17 cells in the development of TMEV-induced demyelinating diseases.
High levels of FoxP3+CD4+ T cells, which constitute a subset of Th cells, appear first in the CNS of virus-infected mice (97, 98). The TLR2-mediated signal induced following TMEV infection may be involved in the early generation of CD25-FoxP3+CD4+ T cells (54, 99, 100). CD25lo FoxP3+CD4+ T cells are found in levels as much as two-fold higher in the CNS of virus-infected SJL mice compared with B6 mice (101). CD25loFoxP3+CD4+ T cells do not display a regulatory function (102), and the presence of a high level of CD25loFoxP3+CD4+ T cells may promote the development of TMEV-induced demyelinating disease (97). CD25loFoxP3+CD4+ T cells appear to undergo trans-differentiation into Th17 cells following the loss of FoxP3 expression (103, 104). Thus, these CD25loFoxP3+CD4+ T cells appearing early in the CNS of TMEV-infected mice may be converted into pathogenic Th17 cells in the presence of excessive cytokines (68, 101). Similarly elevated levels of CD25-FoxP3+CD4+ T cells have been detected in patients with chronic hepatitis B virus infection (105) and systemic lupus (106).
Cytotoxic CD8+ T cells producing IFN-γ and perforin play an important role in protection of mice from developing TMEV-induced demyelinating disease (107–109). Cytotoxic CD8+ T cells recognizing viral determinants appear to participate in causing damages of virus-infected, myelin-producing oligodendrocytes and other cell types in the CNS (110–114). The presence of CD8+ T cells is necessary to manifest clinical symptoms, but the protective role of these cells in the development of TMEV-induced demyelinating disease has also been demonstrated (111–114). Thus, certain CD8+ T cell populations, depending on their specificity and or cytokine profile are likely to play different roles in the pathogenesis of TMEV-induced demyelination.
TMEV productively infects approximately 50% of primary CD20+ B cells and 25% of CD19+CD20+ cells in susceptible SJL mice (27). TMEV-infected B cells express elevated levels of CD69 as well as MHC class II and costimulatory molecules and exhibit elevated levels of antibody production and enhanced antigen-presenting function to T cells. B cell activation after TMEV infection resembles B cells treated with TLR ligands for TLR2, TLR3, TLR4, TLR7, and TLR9 (27). These results strongly suggest that B cell activation following TMEV infection is associated with TLR signals, consistent with previous findings that various TLR-mediated signals activate B cells (115, 116). TMEV infection also triggers B cells of susceptible mice to produce the excessive production of IFN-α/β, IL-6, IL-1β, and PGE2 (27, 117). These innate immune responses further elevate the activation of B cells to produce antibodies to viral and self-antigens and vigorously promote pathogenic Th17 cell responses (27, 117–119).
B cells producing antibodies to TMEV capsid antigens are detected in the demyelinating lesions and spinal fluids of TMEV-infected mice (120–122). Plasma cells producing anti-TMEV antibodies are also detected in the meninges of CNS parenchyma (123). Antibodies to TMEV determinants play a protective role during the early stage of viral infection (124–126). In the absence of CD8+ T cells, antibody response is critically important in protecting mice from Theiler’s virus-induced encephalitis (125). In addition, the pathogenesis of TMEV-induced demyelinating disease is accelerated in mice treated with the monoclonal anti-CD20 antibody (127). However, the contribution of anti-TMEV antibodies to the protection of mice from demyelinating disease is relatively minor compared with the protection by CD4+ Th1 and CD8+ T cells (125, 128).
5 Role of NF-κB activated by TLRs in viral persistence
APCs from susceptible SJL mice are highly susceptible to TMEV infection and the viral infection leads to the activation of NF-κB via TLRs (27, 34, 52). The activation of NF-κB leads to the production of high levels of TNF-α, IL-1β, and IL-6, which are associated with activation of B cells and directional T cell responses (129–131). Type I IFNs produced in consequences of TLR activation contribute to the activation of NF-κB and cellular apoptosis (34, 52, 132, 133). In contrast, high levels of type I or II IFNs provide only transient protection against TMEV infection and thus high levels of these cytokines in susceptible SJL mice may not participate in controlling viral loads in TMEV-infected mice (34, 132, 134). The resistance of TMEV infection against type I IFNs is consistent with previous observations in other viruses (134–136).
Activation of NF-κB is necessary for TMEV replication (45) and consequently the state of host cell activation determines the level of viral replication (137). Following TMEV infection, TLR2, 3, 4, and 7 are associated with the production of various cytokines in different glial cells and professional antigen-presenting cells (27, 39, 52, 54, 138). TLR7 recognizes the single-stranded TMEV RNA genome and TLR3 interacts with the double-stranded RNA replication intermediate in the endosome (48, 52, 139). TMEV infection results in the engagement of various TLRs and other related signals to activate NF-κB, AP-1, and IRFs (54, 55, 140, 141). In turn, these signals result in the production of various cytokines, including TNFα, IL-1β and IL-6. NF-κB activation leads to the elevated expression and activation of TLRs including TLR2/4, which further activate NF-κB at a higher level (54). Such amplified NF-κB signaling further promotes the expression of anti-apoptotic Bcl-2 and Bcl-xL molecules, supporting vigorous TMEV replication (34, 142, 143). Such prevention of apoptosis following TMEV infection may result in further persistent viral replication and excessive cytokine production (Figure 2B).
6 Production of anti-apoptotic cytokines by virus-infected cells
IL-6 is a major cytokine produced following TMEV and other viral infections and displays an anti-apoptotic function (50, 144, 145). IL-6 inhibits the cytolytic function of CD8+ T cells and drives Th17 responses. IL-17 produced by Th17 cells also inhibits cytolytic function of virus-reactive CD8+ T cells, further promoting TMEV persistence (68). Furthermore, IL-6 and IL-17 together synergistically inhibit cytotoxic function of virus-specific CD8+ T cells (79). IL-17 is also known to enhance tumor growth in animals, supporting the inhibitory function of IL-17 on cytotoxic CD8+ T cells (146, 147). Cytotoxic CD8+ T cells and some CD4+ T cells induce the cytolysis of virus-infected cells through the granule exocytosis and or the activation of Fas–FasL pathway (86, 148–151). IL-17 upregulates the expression of Bcl-2 and Bcl-xl molecules via the NF-κB pathway and subsequently these prosurvival molecules protect the target cells from the apoptosis induced by cytotoxic CD4+ and CD8+ T cells (68). Nevertheless, the synergistic inhibition of apoptosis of virus-infected cells by IL-17 and IL-6 may serve as a powerful means for viral persistence. The inhibition of apoptosis extends the life of virus-infected cells, resulting in prolonged viral replication and persistence (Figure 2B). Thus, the interaction between virus and host cells via IL-17 and IL-6 and/or other cytokines results in persistent viral infection and prolonged harmful immune responses including various autoimmune responses, which ultimately lead to the development of TMEV-induced demyelinating disease (152). Similarly, persistent and or repeated infections of COVID-19 appear to stimulate TLRs, leading to cytokine storms and autoimmune responses in pathogenesis (153–156).
7 Viral persistence, continuous TLR signals, and cytokine storms lead to autoimmunity
Chronic infection with TMEV results in antibody responses to self-antigens including myelin basic protein (MBP) in the CNS of infected mice (25, 27, 157). Similarly, CD4+ T cell responses to viral antigens and myelin-associated autoantigens, including MBP and proteolipid protein, have been detected during persistent infection with TMEV (19). In addition, a CD8+ cytotoxic T cell population, recognizing both viral and self-antigens, has been identified in TMEV-infected SJL mice (158). Thus, various immune responses, including antibody, CD4+ T cell, and CD8+ T cell responses to viral and CNS autoantigens, are induced in mice with chronic TMEV infection. Sequestered autoantigens to the CNS may be released following TMEV-induced tissue damage, and these autoantigens subsequently induce autoimmune responses under constant elevated TLR stimulation and cytokine production (19, 27). The initial insults to the CNS by T cells reactive to viral antigens appear to be necessary to the pathogenesis of demyelinating disease (84, 113, 159). Such immune-mediated initial tissue damage in addition to virus-induced cellular apoptosis may be necessary to result in the development of TMEV-induced demyelinating disease.
Following intraperitoneal infection of systemic lupus erythematosus-prone NZBWF1 and BXSB male mice with TMEV or Coxsackie virus, the production of autoantibodies to several nuclear autoantigens has been rapidly accelerated (27). Since these mice have either duplicated or altered TLR genes (115, 160–162), the elevated expression of TLRs and their continuous stimulation is likely responsible for autoimmunity. These results strongly suggest that chronic TMEV infection continuously stimulates preexisting autoimmune cells via virus-induced TLR-mediated polyclonal activation. This notion is supported by the fact that the treatment of cells with the ligands of different TLRs activates B cells and T cells similarly to TMEV infection (27). Because virus-reactive T cell responses are required for the development of TMEV-induced demyelinating disease, immune-mediated tissue damage to the CNS may be necessary (68, 107, 111, 159). Therefore, these anti-viral and autoimmune responses appear to participate in protecting and/or damaging the related tissues (19, 68, 159, 163–165). However, the presence of high levels of proinflammatory cytokines during chronic viral infection may lead to the development of harmful autoimmune responses (166–168). Taken together, persistent TMEV infection leads to continuous stimulation of various TLRs and consequently results in TLR-mediated polyclonal activation of B and T cells. Although the roles of autoimmune responses in the pathogenesis of TMEV-induced demyelinating disease are not certain, they are likely to contribute to the overall pathogenic outcome by participating in further tissue damage and/or cytokine production.
Statements
Author contributions
BK: writing—review and editing, funding acquisition.
Funding
This work was supported by the United States Public Health Service Grants (RO1 NS28752 and RO1 NS33008) and a grant from the National Multiple Sclerosis Society (RG 4001-A6).
Acknowledgments
I acknowledge all the colleagues who have participated in original contribution to this research in the past years.
Conflict of interest
The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Abbreviations
MS, multiple sclerosis; CNS, central nervous system; TMEV, Theiler’s murine encephalomyelitis virus; TMEV-IDD, TMEV-induced demyelinating disease; Tg, transgenic mice; TCR, T cell receptor; MHC, major histocompatibility complex.
References
1
TheilerM. Spontaneous encephalomyelitis of mice-a new virus disease. J Exp Med (1934) 80:122. doi: 10.1126/science.80.2066.122-b
2
LiptonHL. Theiler's virus infection in mice: an unusual biphasic disease process leading to demyelination infect. Immun (1975) 11:1147–55. doi: 10.1128/iai.11.5.1147-1155.1975
3
NitayaphanSOmilianowskiDTothMMParksGDRueckertRRPalmenbergACet al. Relationship of theiler's murine encephalomyelitis viruses to the cardiovirus genus of picornaviruses. Intervirology (1986) 26:140–8. doi: 10.1159/000149693
4
AchesonNH. Fundamentals of molecular virology. 2nd ed. John Wiley & Sons, Inc (2011).
5
DanielsJBPappenheimerAMRichardsonS. Observations on encephalomyelitis of mice (DA strain). J Exp Med (1952) 96:517. doi: 10.1084/jem.96.6.517
6
LehrichJRArnasonBGHochbergFH. Demyelinative myelopathy in mice induced by the DA virus. J Neurol Sci (1976) 29(2-4):149–60. doi: 10.1016/0022-510X(76)90167-2
7
LiptonHLFriedmannA. Purification of theiler's murine encephalomyelitis virus and analysis of the structural virion polypeptides: correlation of the polypeptide profile with virulence. J Virol (1980) 33:1165–72. doi: 10.1128/jvi.33.3.1165-1172.1980
8
Dal CantoMCLiptonHL. Primary demyelination in theiler's virus infection. an ultrastructural study. Lab Invest (1975) 33:626–37.
9
LiptonHLDal CantoMC. The TO strains of theiler’s viruses cause "slow virus-like" infections in mice. Ann Neurol (1979) 6:25–8. doi: 10.1002/ana.410060106
10
JohnsonRT. The possible viral etiology of multiple sclerosis. Adv Neurol (1975) 13:1–46.
11
McFarlinDEMcFarlandHF. Multiple sclerosis (first of two parts). N Engl J Med (1982) 307(19):1183– 8. doi: 10.1056/NEJM198211043071905
12
SoldanSSBertiRSalemNSecchieroPFlamandLCalabresiPAet al. Association of human herpes virus 6 (HHV-6) with multiple sclerosis: increased IgM response to HHV-6 early antigen and detection of serum HHV-6 DNA. Nat Med (1997) 3(12):1394–7. doi: 10.1038/nm1297-1394
13
AkhyaniNBertiRBrennanMBSoldanSSEatonJMMcFarlandHFet al. Tissue distribution and variant characterization of human herpesvirus (HHV)-6: increased prevalence of HHV-6A in patients with multiple sclerosis. J Infect Dis (2000) 182(5):1321–5. doi: 10.1086/315893
14
MartinezAAlvarez-LafuenteRMasABartolomeMGarcia-MontojoMde Las HerasVet al. Environment-gene interaction in multiple sclerosis: human herpesvirus 6 and MHC2TA. Hum Immunol (2007) 68(8):685–9. doi: 10.1016/j.humimm.2007.05.005
15
Adams RaVM. Principles of neurology. New York: McGraw Hill (1977). p. 1041.
16
BuchmeierMJLaneTE. Viral-induced neurodegenerative disease. Curr Opin Microbiol (1999) 2(4):398–402. doi: 10.1016/S1369-5274(99)80070-8
17
WegeHSiddellSter MeulenV. The biology and pathogenesis of coronaviruses. Curr Top Microbiol Immunol (1982) 99:165–200. doi: 10.1007/978-3-642-68528-6_5
18
Dal CantoMCKimBSMillerSDMelvoldRW. Theiler's murine encephalomyelitis virus (TMEV)-induced demyelination: a model for human multiple clerosis. Methods (1996) 10(3):453–61. doi: 10.1006/meth.1996.0123
19
MillerSDVanderlugtCLBegolkaWSPaoWYauchRLNevilleKLet al. Persistent infection with theiler's virus leads to CNS autoimmunity via epitope spreading. Nat Med (1997) 3(10):1133–6. doi: 10.1038/nm1097-1133
20
LiangZKumarASJonesMSKnowlesNJLiptonHL. Phylogenetic analysis of the species theilovirus: emerging murine and human pathogens. J Virol (2008) 82(23):11545–54. doi: 10.1128/JVI.01160-08
21
ChiuCYGreningerALKanadaKKwokTFischerKFRunckelCet al. Identification of cardioviruses related to theiler's murine encephalomyelitis virus in human infections. Proc Natl Acad Sci U.S.A. (2008) 105(37):14124–9. doi: 10.1073/pnas.0805968105
22
ZollJErkens HulshofSLankeKVerduyn LunelFMelchersWJSchoondermark-van de VenEet al. Saffold virus, a human theiler's-like cardiovirus, is ubiquitous and causes infection early in life. PloS Pathog (2009) 5(5):e1000416. doi: 10.1371/journal.ppat.1000416
23
WisniewskiHMBloomBR. Primary demyelination as a nonspecific consequence of a cell-mediated immune reaction. J Exp Med (1975) 141(2):346–59. doi: 10.1084/jem.141.2.346
24
ClatchRJLiptonHLMillerSD. Characterization of theiler's murine encephalomyelitis virus (TMEV)-specific delayed-type hypersensitivity responses in TMEV-induced demyelinating disease: correlation with clinical signs. J Immunol (1986) 136:920–7. doi: 10.4049/jimmunol.136.3.920
25
RauchHCMontgomeryINHinmanCLHarbWBenjaminsJA. Chronic theiler's virus infection in mice: appearance of myelin basic protein in the cerebrospinal fluid and serum antibody directed against MBP. J Neuroimmunol (1987) 14:35–48. doi: 10.1016/0165-5728(87)90099-3
26
YamadaMZurbriggenAFujinamiRS. Monoclonal antibody to theiler's murine encephalomyelitis virus defines a determinant on myelin and oligodendrocytes, and augments demyelination in experimental allergic encephalomyelitis. J Exp Med (1990) 171:1893–907. doi: 10.1084/jem.171.6.1893
27
JinYHKimCXHuangJKimBS. Infection and activation of b cells by theiler's murine encephalomyelitis virus (TMEV) leads to autoantibody production in an infectious model of multiple sclerosis. Cells (2020) 9(8):1787. doi: 10.3390/cells9081787
28
LiptonHLDal CantoMC. Susceptibility of inbred mice to chronic central nervous system infection by theiler's murine encephalomyelitis virus. Infect Immun (1979) 26:369–74. doi: 10.1128/iai.26.1.369-374.1979
29
RodriguezMDavidCS. Demyelination induced by theiler's virus: influence of the h-2 haplotype. J Immunol (1985) 135:2145–8. doi: 10.4049/jimmunol.135.3.2145
30
JinYHMohindruMKangMHFullerACKangBGalloDet al. Differential virus replication, cytokine production, and antigen-presenting function by microglia from susceptible and resistant mice infected with theiler's virus. J Virol (2007) 81(21):11690–702. doi: 10.1128/JVI.01034-07
31
AndersonRHartingEFreyMSLeibowitzJLMirandaRC. Theiler's murine encephalomyelitis virus induces rapid necrosis and delayed apoptosis in myelinated mouse cerebellar explant cultures. Brain Res (2000) 868(2):259–67. doi: 10.1016/S0006-8993(00)02338-6
32
PalmaJPKimBS. Induction of selected chemokines in glial cells infected with theiler's virus. J Neuroimmunol (2001) 117(1-2):166–70. doi: 10.1016/S0165-5728(01)00326-5
33
ZhengLCalenoffMADal CantoMC. Astrocytes, not microglia, are the main cells responsible for viral persistence in theiler's murine encephalomyelitis virus infection leading to demyelination. J Neuroimmunol (2001) 118(2):256–67. doi: 10.1016/S0165-5728(01)00338-1
34
HouWSoEYKimBS. Role of dendritic cells in differential susceptibility to viral demyelinating disease. PloS Pathog (2007) 3(8):e124. doi: 10.1371/journal.ppat.0030124
35
JinYHKangBKangHSKohCSKimBS. Endothelin-1 contributes to the development of virus-induced demyelinating disease. J Neuroinflamm (2020) 17(1):307. doi: 10.1186/s12974-020-01986-z
36
ClatchRJMillerSDMetznerRDal CantoMCLiptonHL. Monocytes/macrophages isolated from the mouse central nervous system contain infectious theiler's murine encephalomyelitis virus (TMEV). Virology (1990) 176:244–54. doi: 10.1016/0042-6822(90)90249-Q
37
ClatchRJMelvoldRWMillerSDLiptonHL. Theiler's murine encephalomyelitis virus (TMEV)-induced demyelinating disease in mice is influenced by the h-2D region: correlation with TEMV-specific delayed-type hypersensitivity. J Immunol (1985) 135(2):1408–14. doi: 10.4049/jimmunol.135.2.1408
38
OlsonJKMillerSD. Microglia initiate central nervous system innate and adaptive immune responses through multiple TLRs. J Immunol (2004) 173(6):3916–24. doi: 10.4049/jimmunol.173.6.3916
39
JinYHKangHSHouWMengLKimBS. The level of viral infection of antigen-presenting cells correlates with the level of development of theiler's murine encephalomyelitis virus-induced demyelinating disease. J Virol (2015) 89(3):1867–78. doi: 10.1128/JVI.02471-14
40
LiptonHLMelvoldR. Genetic analysis of susceptibility to theiler's virus-induced demyelinating disease in mice. J Immunol (1984) 132:1821–5. doi: 10.4049/jimmunol.132.4.1821
41
LiptonHLKumarASTrottierM. Theiler's virus persistence in the central nervous system of mice is associated with continuous viral replication and a difference in outcome of infection of infiltrating macrophages versus oligodendrocytes. Virus Res (2005) 111(2):214–23. doi: 10.1016/j.virusres.2005.04.010
42
AkiraS. TLR signaling. Curr Top Microbiol Immunol (2006) 311:1–16. doi: 10.1007/3-540-32636-7_1
43
DieboldSSKaishoTHemmiHAkiraS. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science (2004) 303:1529–31. doi: 10.1126/science.1093616
44
SonKNBeckerRPKallioPLiptonHL. Theiler's virus-induced intrinsic apoptosis in M1-d macrophages is bax mediated and restricts virus infectivity: a mechanism for persistence of a cytolytic virus. J Virol (2008) 82(9):4502–10. doi: 10.1128/JVI.02349-07
45
KangMHSoEYParkHKimBS. Replication of theiler's virus requires NF-kappaB-activation: higher viral replication and spreading in astrocytes from susceptible mice. Glia (2008) 56(9):942–53. doi: 10.1002/glia.20668
46
SchneiderKMWatsonNBMinchenbergSBMassaPT. The influence of macrophage growth factors on theiler's murine encephalomyelitis virus (TMEV) infection and activation of macrophages. Cytokine (2018) 102:83–93. doi: 10.1016/j.schres.2017.08.003
47
ChangJRZaczynskaEKatsetosCDPlatsoucasCDOleszakEL. Differential expression of TGF-beta, IL-2, and other cytokines in the CNS of theiler's murine encephalomyelitis virus-infected susceptible and resistant strains of mice. Virology (2000) 278(2):346–60. doi: 10.1006/viro.2000.0646
48
PetroTM. Disparate expression of IL-12 by SJL/J and B10.S macrophages during theiler's virus infection is associated with activity of TLR7 and mitogen-activated protein kinases. Microbes Infect (2005) 7:224–32. doi: 10.1016/j.micinf.2004.10.014
49
MooreTCBushKLCodyLBrownDMPetroTM. Control of early theiler's murine encephalomyelitis virus replication in macrophages by interleukin-6 occurs in conjunction with STAT1 activation and nitric oxide production. J Virol (2012) 86(19):10841–51. doi: 10.1128/JVI.01402-12
50
JinYHKaneyamaTKangMHKangHSKohCSKimBS. TLR3 signaling is either protective or pathogenic for the development of theiler's virus-induced demyelinating disease depending on the time of viral infection. J Neuroinflamm (2011) 8:178. doi: 10.1186/1742-2094-8-178
51
PullenLCParkSHMillerSDDal CantoMCKimBS. Treatment with bacterial LPS renders genetically resistant C57BL/6 mice susceptible to theiler's virus-induced demyelinating disease. J Immunol (1995) 155(9):4497–503. doi: 10.4049/jimmunol.155.9.4497
52
SoEYKangMHKimBS. Induction of chemokine and cytokine genes in astrocytes following infection with theiler’s murine encephalomyelitis virus is mediated by the toll-like receptor 3. Glia (2006) 53:858–67. doi: 10.1002/glia.20346
53
TurrinNP. Central nervous system toll-like receptor expression in response to theiler’s murine encephalomyelitis virus-induced demyelinating disese in resistnt and susceptible mouse strains. Virol J (2008) 5:154. doi: 10.1186/1743-422X-5-154
54
SoEYKimBS. Theiler's virus infection induces TLR3-dependent upregulation of TLR2 critical for proinflammatory cytokine production. Glia (2009) 57:1216–26. doi: 10.1002/glia.20843
55
JinYHKimSJSoEYMengLColonnaMKimBS. Melanoma differentiation-associated gene 5 is critical for protection against theiler's virus-induced demyelinating disease. J Virol (2012) 86:1531–43. doi: 10.1128/JVI.06457-11
56
PalmaJPKimBS. The scope and activation mechanisms of chemokine gene expression in primary astrocytes following infection with theiler's virus. J Neuroimmunol (2004) 149:121–9. doi: 10.1016/j.jneuroim.2003.12.025
57
RubioNSanz-RodriguezFLiptonHL. Theiler's virus induces the MIP-2 chemokine (CXCL2) in astrocytes from genetically susceptible but not from resistant mouse strains. Cell Immunol (2006) 239:31–40. doi: 10.1016/j.cellimm.2006.03.003
58
RubioNSanz-RodriguezF. Induction of the CXCL1 (KC) chemokine in mouse astrocytes by infection with the murine encephalomyelitis virus of theiler. Virology (2007) 358:98–108. doi: 10.1016/j.virol.2006.08.003
59
AsensioVCCampbellIL. Chemokine gene expression in the brains of mice with lymphocytic choriomeningitis. J Virol (1997) 71:7832–40. doi: 10.1128/jvi.71.10.7832-7840.1997
60
LaneTEAsensioVCYuNPaolettiADCampbellILBuchmeierMJ. Dynamic regulation of alpha- and beta-chemokine expression in the central nervous system during mouse hepatitis virus-induced demyelinating disease. J Immunol (1998) 180:970–8. doi: 10.4049/jimmunol.160.2.970
61
HoffmanLMEifeBTBegolkaWSMillerSDKarpusWJ. Central nervous system chemokine expression during theiler's virus-induced demyelinating disease. J Neurovirol (1999) 5:635–42. doi: 10.3109/13550289909021292
62
NoeKHCenciarelliCMoyerSARotaPAShinML. Requirements for measles virus induction of RANTES chemokine in human astrocytoma-derived U373 cells. J Virol (1999) 73:3117–24. doi: 10.1128/JVI.73.4.3117-3124.1999
63
GuidottiLGChisariFV. Noncytolytic control of viral infections by the innate and adaptive immune response. Annu Rev Immunol (2001) 19:65–91. doi: 10.1146/annurev.immunol.19.1.65
64
LudewigBJuntTHengartnerBZinkernagelRM. Dendritic cells in autoimmune diseases. Curr Opin Immunol (2001) 13:657–62. doi: 10.1016/S0952-7915(01)00275-8
65
VeckmanVÖsterlundPFagerlundRMelénKMatikainenSJulkunenI. TNF-α and IFN-α enhance influenza-a-virus-induced chemokine gene expression in human A549 lung epithelial cells. Virology (2006) 345:96–104. doi: 10.1016/j.virol.2005.09.043
66
PalmaJPKwonDClipstonNAKimBS. Infection with theiler's murine encephalomyelitis virus directly induces proinflammatory cytokines in primary astrocytes via NF-kappaB activation: potential role for the initiation of demyelinating disease. J Virol (2003) 77:6322–31. doi: 10.1128/JVI.77.11.6322-6331.2003
67
OlsonJK. Effect of the innate immune response on development of theiler's murine encephalomyelitis virus-induced demyelinating disease. J Neurovirol (2014) 20:427–36. doi: 10.1007/s13365-014-0262-6
68
HouWKangHSKimBS. Th17 cells enhance viral persistence and inhibit T cell cytotoxicity in a model of chronic virus infection. J Exp Med (2009) 206(2):313–28. doi: 10.1084/jem.20082030
69
InoueAKohCSYamazakiMIchikawaMIsobeMIshiharaYet al. Anti-adhesion molecule therapy in theiler's murine encephalomyelitis virus-induced demyelinating disease. Int Immunol (1997) 9(12):1837–47. doi: 10.1093/intimm/9.12.1837
70
OlsonJKGirvinAMMillerSD. Direct activation of innate and antigen-presenting functions of microglia following infection with theiler's virus. J Virol (2001) 75(20):9780–9. doi: 10.1128/JVI.75.20.9780-9789.2001
71
PoznerRGBerriaMINegrottoSSchattnerMGomezRM. Differential astrocyte response to theiler's murine encephalomyelitis virus infection. Intervirology (2005) 48(5):279–84. doi: 10.1159/000085095
72
RubioNSanz-RodriguezFArevaloMA. Up-regulation of the vascular cell adhesion molecule-1 (VCAM-1) induced by theiler's murine encephalomyelitis virus infection of murine brain astrocytes. Cell Commun Adhes (2010) 17(3):57–68. doi: 10.3109/15419061.2010.507827
73
KimBSJinYHMengLHouWKangHSParkHSet al. IL-1 signal affects both protection and pathogenesis of virus-induced chronic CNS demyelinating disease. J Neuroinflamm (2012) 9:217. doi: 10.1186/1742-2094-9-217
74
KimSJJinYHKimBS. Prostaglandin E2 produced following infection with theiler's virus promotes the pathogenesis of demyelinating disease. PloS One (2017) 12(4):e0176406. doi: 10.1371/journal.pone.0176406
75
AgostiniLMartinonFBurnsKMcDermottMFHawkinsPNTschoppJ. NALP3 forms an IL-1beta-processing inflammasome with increased activity in muckle-wells autoinflammatory disorder. Immunity (2004) 20:319–25. doi: 10.1016/S1074-7613(04)00046-9
76
SwansonKVDengMTingJP. The NLRP3 inflammasome: molecular activation and regulation to therapeutics. Nat Rev Immunol (2019) 19(8):477–89. doi: 10.1038/s41577-019-0165-0
77
HwangSYKimJYKimKWParkMKMoonYKimWUet al. IL-17 induces production of IL-6 and IL-8 in rheumatoid arthritis synovial fibroblasts via NF-kappaB- and PI3-kinase/Akt-dependent pathways. Arthritis Res Ther (2004) 6:R120–8. doi: 10.1186/ar1038
78
WangLYiTKortylewskiMPardollDWZengDYuH. IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J Exp Med (2009) 206:1457–64. doi: 10.1084/jem.20090207
79
HouWJinYHKangHSKimBS. Interleukin-6 (IL-6) and IL-17 synergistically promote viral persistence by inhibiting cellular apoptosis and cytotoxic T cell function. J Virol (2014) 88(15):8479–89. doi: 10.1128/JVI.00724-14
80
WeinlichRBortoluciKRChehabCFSerezaniCHUlbrichAGPeters-GoldenMet al. TLR4/MYD88-dependent, LPS-induced synthesis of PGE2 by macrophages or dendritic cells prevents anti-CD3-mediated CD95L upregulation in T cells. Cell Death Differ (2008) 15:1901–9. doi: 10.1038/cdd.2008.128
81
JinYHHouWKangHSKohCSKimBS. The role of interleukin-6 in the expression of PD-1 and PDL-1 on central nervous system cells following infection with theiler's murine encephalomyelitis virus. J Virol (2013) 87:11538–51. doi: 10.1128/JVI.01967-13
82
ChanLCLiCWXiaWHsuJMLeeHHChaJHet al. IL-6/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion. J Clin Invest (2019) 129(8):3324–38. doi: 10.1172/JCI126022
83
Ben-SassonSZHu-LiJQuielJCaucheltauxSRatnerMShapiraIet al. IL-1 acts directly on CD4 T cells to enhance their antigen-driven expansion and differentiation. Proc Natl Acad Sci USA (2009) 106:7119–24. doi: 10.1073/pnas.0902745106
84
PalmaJPYauchRLLangSKimBS. Potential role of CD4+ T cell-mediated apoptosis of activated astrocytes in theiler's virus-induced demyelination. J Immunol (1999) 162:6543–51. doi: 10.4049/jimmunol.162.11.6543
85
CraneMAYauchRDal CantoMCKimBS. Effect of immunization with theiler's virus on the course of demyelinating disease. J Neuroimmunol (1993) 45(1-2):67–73. doi: 10.1016/0165-5728(93)90165-U
86
KangBKangHKKimBS. Identification of capsid epitopes of theiler's virus recognized by CNS-infiltrating CD4(+) T cells from virus-infected C57BL/6 mice. Virus Res (2005) 108(1-2):57–61. doi: 10.1016/j.virusres.2004.08.001
87
RodriguezMRoosRPMcGavernDZoeckleinLPavelkoKSangHet al. The CD4-mediated immune response is critical in determining the outcome of infection using theiler's viruses with VP1 capsid protein point mutations. Virology (2000) 275(1):9–19. doi: 10.1006/viro.2000.0493
88
FietteLAubertCMullerUHuangSAguetMBrahicMet al. Theiler's virus infection of 129Sv mice that lack the interferon alpha/beta or interferon gamma receptors. J Exp Med (1995) 181(6):2069–76. doi: 10.1084/jem.181.6.2069
89
RodriguezMZoeckleinLJHoweCLPavelkoKDGamezJDNakaneSet al. Gamma interferon is critical for neuronal viral clearance and protection in a susceptible mouse strain following early intracranial theiler's murine encephalomyelitis virus infection. J Virol (2003) 77(22):12252–65. doi: 10.1128/JVI.77.22.12252-12265.2003
90
PullenLCMillerSDDalCantoMCvan der MeidePHKimBS. Alteration in the level of interferon-gamma results in acceleration of theiler's virus-induced demyelinating disease. J Neuroimmunol (1994) 55:143–52. doi: 10.1016/0165-5728(94)90004-3
91
RodriguezMPavelkoKCoffmanRL. Gamma interferon is critical for resistance to theiler's virus-induced demyelination. J Virol (1995) 69(11):7286–90. doi: 10.1128/jvi.69.11.7286-7290.1995
92
HarringtonLEHattonRDManganPRTurnerHMurphyTLMurphyKMet al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol (2005) 6(11):1123–32. doi: 10.1038/ni1254
93
ParkHLiZYangXOChangSHNurievaRWangYHet al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol (2005) 6(11):1133–41. doi: 10.1038/ni1261
94
SteinmanL. A brief history of T(H)17, the first major revision in the T(H)1/T(H)2 hypothesis of T cell-mediated tissue damage. Nat Med (2007) 13(2):139–45. doi: 10.1038/nm1551
95
VeldhoenMHockingRJAtkinsCJLocksleyRMStockingerB. TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity (2006) 24(2):179–89. doi: 10.1016/j.immuni.2006.01.001
96
MartinezNESatoFKawaiEOmuraSTakahashiSYohKet al. Th17-biased RORgammat transgenic mice become susceptible to a viral model for multiple sclerosis. Brain behavior immunit. (2015) 43:86–97. doi: 10.1016/j.bbi.2014.07.008
97
RichardsMHGettsMTPodojilJRJinYHKimBSMillerSD. Virus expanded regulatory T cells control disease severity in the theiler's virus mouse model of MS. J Autoimmun (2011) 36(2):142–54. doi: 10.1016/j.jaut.2010.12.005
98
ZhaoJZhaoJPerlmanS. Virus-specific regulatory T cells ameliorate encephalitis by repressing effector T cell functions from priming to effector stages. PloS Pathog (2014) 10(8):e1004279. doi: 10.1371/journal.ppat.1004279
99
NawijnMCMottaACGrasRShirinbakSMaaziHvan OosterhoutAJ. TLR-2 activation induces regulatory T cells and long-term suppression of asthma manifestations in mice. PloS One (2013) 8(2):e55307. doi: 10.1371/journal.pone.0055307
100
YamazakiSOkadaKMaruyamaAMatsumotoMYagitaHSeyaT. TLR2-dependent induction of IL-10 and Foxp3+ CD25+ CD4+ regulatory T cells prevents effective anti-tumor immunity induced by Pam2 lipopeptides in vivo. PloS One (2011) 6(4):e18833. doi: 10.1371/journal.pone.0018833
101
KangHSHouWKimBS. Rapid expansion of virus-specific CD4+ T cell types in the CNS of susceptible mice infected with theiler’s virus. Int J Mol Sci (2020) 21:7719. doi: 10.3390/ijms21207719
102
ZelenaySLopes-CarvalhoTCaramalhoIMoraes-FontesMFRebeloMDemengeotJ. Foxp3+ CD25- CD4 T cells constitute a reservoir of committed regulatory cells that regain CD25 expression upon homeostatic expansion. Proc Natl Acad Sci U.S.A. (2005) 102(11):4091–6. doi: 10.1073/pnas.0408679102
103
RadhakrishnanSCabreraRSchenkELNava-ParadaPBellMPVan KeulenVPet al. Reprogrammed FoxP3+ T regulatory cells become IL-17+ antigen-specific autoimmune effectors in vitro and in vivo. J Immunol (2008) 181(5):3137–47. doi: 10.4049/jimmunol.181.5.3137
104
KomatsuNOkamotoKSawaSNakashimaTOh-horaMKodamaTet al. Pathogenic conversion of Foxp3+ T cells into TH17 cells in autoimmune arthritis. Nat Med (2014) 20(1):62–8. doi: 10.1038/nm.3432
105
StoopJNClaassenMAWoltmanAMBindaRSKuipersEJJanssenHLet al. Intrahepatic regulatory T cells are phenotypically distinct from their peripheral counterparts in chronic HBV patients. Clin Immunol (2008) 129(3):419–27. doi: 10.1016/j.clim.2008.07.029
106
BonelliMSavitskayaASteinerCWRathESmolenJSScheineckerC. Phenotypic and functional analysis of CD4+ CD25- Foxp3+ T cells in patients with systemic lupus erythematosus. J Immunol (2009) 182(3):1689–95. doi: 10.4049/jimmunol.182.3.1689
107
MurrayPDMcGavernDBLinXNjengaMKLeibowitzJPeaseLRet al. Perforin-dependent neurologic injury in a viral model of multiple sclerosis. J Neurosci (1998) 18(18):7306–14. doi: 10.1523/JNEUROSCI.18-18-07306.1998
108
PalmaJPLeeHGMohindruMKangBSDalCantoMMillerSDet al. Enhanced susceptibility to theiler's virus-induced demyelinating disease in perforin-deficient mice. J Neuroimmunol (2001) 116:125–35. doi: 10.1016/S0165-5728(01)00293-4
109
Pena RossiCMcAllisterAFietteLBrahicM. Theiler's virus infection induces a specific cytotoxic T lymphocyte response. Cell Immunol (1991) 138:341–8. doi: 10.1016/0008-8749(91)90158-8
110
LindsleyMDThiemannRRodriguezM. Cytotoxic T cells isolated from the central nervous systems of mice infected with theiler’s virus. J Virol (1991) 65:6612–20. doi: 10.1128/jvi.65.12.6612-6620.1991
111
Rivera-QuinonesCMcGovernDSchmeizerJDHunterSFLowPARodriguezM. Absence of neurological deficits following extensive demyelination in a class I-deficient murine model of multiple sclerosis. Nat Med (1998) 4:187–93. doi: 10.1038/nm0298-187
112
BorrowPTonksPWelshCJNashAA. The role of CD8+T cells in the acute and chronic phases of theiler's murine encephalomyelitis virus-induced disease in mice. J Gen Virol (1992) 73:1861–5. doi: 10.1099/0022-1317-73-7-1861
113
MyoungJHouWKangBLymanMAKangJAKimBS. The immunodominant CD8+ T cell epitope region of theiler's virus in resistant C57BL/6 mice is critical for anti-viral immune responses, viral persistence, and binding to the host cells. Virology (2007) 360:159–71. doi: 10.1016/j.virol.2006.09.045
114
BegolkaWSHaynesLMOlsonJKPadillaJNevilleKLDalCantoMet al. CD8-deficient SJL mice display enhanced susceptibility to theiler's virus infection and increased demyelinating pathology. J Neurovirol (2001) 7:409–20. doi: 10.1080/135502801753170264
115
Santiago-RaberMLBaudinoLIzulS. Emerging roles of TLR7 and TLR9 in murine SLE. J Autoimmun (2009) 33:231–8. doi: 10.1016/j.jaut.2009.10.001
116
MillsKH. TLR-dependent T cell activation in autoimmunity. Nat Rev Immunol (2011) 11:807–22. doi: 10.1038/nri3095
117
KieferKOropalloMACancroMPMarshak-RothsteinA. Role of type I interferons in the activation of autoreactive b cells. Immunol Cell Biol (2012) 90:498–504. doi: 10.1038/icb.2012.10
118
KishimotoT. Interleukin-6: from basic science to medicine–40 years in immunology. Annu Rev Immunol (2005) 23:1–21. doi: 10.1146/annurev.immunol.23.021704.115806
119
KunoKMatsushimaK. The IL-1 receptor signaling pathway. J Leukoc Biol (1994) 56:542–7. doi: 10.1002/jlb.56.5.542
120
CashEBandeiraAChirinianSBrahicM. Characterization of b lymphocytes present in the demyelinating lesions induced by theiler's virus. J Immunol (1989) 143(3):984–8. doi: 10.4049/jimmunol.143.3.984
121
RoosRPNalefskiEANitayaphanSVariakojisRSinghKK. An isoelectric focusing overlay study of the humoral immune response in theiler's virus demyelinating disease. JNeuroimmunol (1987) 13:305–14. doi: 10.1016/0165-5728(87)90066-X
122
ZurbriggenAFujinamiRS. A neutralization-resistant theiler's virus variant produces an altered disease pattern in the mouse central nervous system. J Virol (1989) 63:1505–13. doi: 10.1128/jvi.63.4.1505-1513.1989
123
PachnerARLiLLagunoffD. Plasma cells in the central nervous system in the theiler's virus model of multiple sclerosis. J Neuroimmunol (2011) 232(1-2):35–40. doi: 10.1016/j.jneuroim.2010.09.026
124
CameronKZhangXSealBRodriguezMNjengaMK. Antigens to viral capsid and non-capsid proteins are present in brain tissues and antibodies in sera of theiler's virus-infected mice. J Virol Methods (2001) 91(1):11–9. doi: 10.1016/S0166-0934(00)00246-9
125
KangBSPalmaJPLymanMADal CantoMKimBS. Antibody response is required for protection from theiler's virus-induced encephalitis in C57BL/6 mice in the absence of CD8(+) T cells. Virology (2005) 340(1):84–94. doi: 10.1016/j.virol.2005.06.028
126
KimBSChoeYKCraneMAJueCR. Identification and localization of a limited number of predominant conformation-independent antibody epitopes of theiler's murine encephalomyelitus virus. Immunol Lett (1992) 31(2):199–205. doi: 10.1016/0165-2478(92)90146-F
127
GilliFLiLCampbellSJAnthonyDCPachnerAR. The effect of b-cell depletion in the theiler's model of multiple sclerosis. J Neurol Sci (2015) 359(1-2):40–7. doi: 10.1016/j.jns.2015.10.012
128
InoueAChoeYKKimBS. Analysis of antibody responses to predominant linear epitopes of theiler's murine encephalomyelitis virus. J Virol (1994) 68:3324–33. doi: 10.1128/jvi.68.5.3324-3333.1994
129
DelhayeSPaulSBlakqoriGMinetMWeberFStaeheliPet al. Neurons produce type I interferon during viral encephalitis. Proc Natl Acad Sci U.S.A. (2006) 103(20):7835–40. doi: 10.1073/pnas.0602460103
130
RubioNPalomoMAlcamiA. Interferon-alpha/beta genes are up-regulated in murine brain astrocytes after infection with theiler's murine encephalomyelitis virus. J Interferon Cytokine Res (2010) 30(4):253–62. doi: 10.1089/jir.2009.0050
131
JinYHHouWKimSJFullerACKangBGoingsGet al. Type I interferon signals control theiler's virus infection site, cellular infiltration and T cell stimulation in the CNS. J Neuroimmunol (2010) 226:27–37. doi: 10.1016/j.jneuroim.2010.05.028
132
JelachichMLLipyonHL. Restricted theiler's murine encephalomyelitis virus infection in murine macrophages induces apoptosis. J Gen Virol (1999) 80:1701–5. doi: 10.1099/0022-1317-80-7-1701
133
YangCHMurtiAPfefferSRBasuLKimJGPfeffeLM. IFNα/β promotes cell survival by activating NF-κB. Proc Nat Acad Sci USA (2000) 97:13631–6. doi: 10.1073/pnas.250477397
134
DaherKASamuelCE. Mechanism of interferon action. differential effect of interferon on the synthesis of simian virus 40 and reovirus polypeptides in monkey kidney cells. Virology (1982) 117:379–90. doi: 10.1016/0042-6822(82)90477-9
135
AtreyaPLKulkamiS. Respiratory syncytial virus strain A2 is resistant to the antiviral effects of type I interferons and human MxA. Virology (1999) 261:227–41. doi: 10.1006/viro.1999.9835
136
HoLJHungLFWengCYWuWLChouPLinYLet al. Dengue virus type 2 antagonizes IFN-alpha but not IFN-gamma antiviral effect via down-regulating Tyk2-STAT signaling in the human dendritic cell. J Immunol (2005) 174:8163–72. doi: 10.4049/jimmunol.174.12.8163
137
JelachichMLBandyopadhyayPBlumKLiptonHL. Theiler's virus growth in murine macrophage cell lines depends on the state of differentiation. Virology (1995) 209:437–44. doi: 10.1006/viro.1995.1276
138
TurrinNP. Central nervous system toll-like receptor expression in response to theiler's murine encephalomyelitis virus-induced demyelination disease in resistant and susceptible mouse strains. Virol J (2008) 5:154. doi: 10.1186/1743-422X-5-154
139
AkiraSHemmiH. Recognition of pathogen-associated molecular patterns by TLR family. Immunol Lett (2003) 85:85–95. doi: 10.1016/S0165-2478(02)00228-6
140
DieboldSSKaishoTHemmiHAkiraSSousaRe. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science (2004) 303:1529–31. doi: 10.1126/science.1093616
141
KawaiTAkiraS. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity (2011) 34:637–50. doi: 10.1016/j.immuni.2011.05.006
142
MattsonMPMeffertMK. Roles for NF-kappaB in nerve cell survival, plasticity, and disease. Cell Deth Difer (2006) 13(5):852–60. doi: 10.1038/sj.cdd.4401837
143
SarnicoI. NF-kappaB dimers in the regulation of neuronal survival. Int Rev Neurobiol (2009) 85:351–62. doi: 10.1016/S0074-7742(09)85024-1
144
HsiehCYChenCAHuangCYChangMCLeeCNSuYNet al. IL-6-encoding tumor antigen generates potent cancer immunotherapy through antigen processing and anti-apoptotic pathways. Mol Ther (2007) 15(10):1890–7. doi: 10.1038/sj.mt.6300243
145
JourdanMVeyruneJLDe VosJRedalNCoudercGKleinB. A major role for mcl-1 antiapoptotic protein in the IL-6-induced survival of human myeloma cells. Oncogene (2003) 22(19):2950–9. doi: 10.1038/sj.onc.1206423
146
AsadzadehZMohammadiHSafarzadehEHemmatzadehMMahdian-ShakibAJadidi-NiaraghFet al. The paradox of Th17 cell functions in tumor immunity. Cell Immunol (2017) 322:15–25. doi: 10.1016/j.cellimm.2017.10.015
147
VarikutiSOghumuSElbazMVolpedoGAhirwarDKAlarconPCet al. STAT1 gene deficient mice develop accelerated breast cancer growth and metastasis which is reduced by IL-17 blockade. Oncoimmunol (2017) 6:e1361088. doi: 10.1080/2162402X.2017.1361088
148
KagiDVignauxFLedermannBBurkiKDepraetereVNagataSet al. Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. Science (1994) 265:528–30. doi: 10.1126/science.7518614
149
LowinBHahneMMattmannCTschoppJ. Cytolytic T-cell cytotoxicity is mediated through perforin and fas lytic pathways. Proc Natl Acad Sci USA (1994) 91:11571–5. doi: 10.1073/pnas.91.24.11571
150
HartyJTTvinnereimARWhiteDW. CD8+ T cell effector mechanisms in resistance to infection. Ann Rev Immunol (2000) 18:275–308. doi: 10.1146/annurev.immunol.18.1.275
151
JellisonERKimSKWelshRM. Cutting edge: MHC class II-restricted killing in vivo during viral infection. J Immunol (2005) 174:614–8. doi: 10.4049/jimmunol.174.2.614
152
KimBS. Excessive innate immunity steers pathogenic adaptive immunity in the development of theiler's virus-induced demyelinating disease. (2021) 22(10):5254. doi: 10.3390/ijms22105254
153
KhanmohammadiSRezaeiN. Role of toll-like receptors in the pathogenesis of COVID-19. J Med Virol (2021) 93:2735–9. doi: 10.1002/jmv.26826
154
MabreyFLMorrellEDWurfelMM. TLRs in COVID-19: how they drive immunopathology and the rationale for modulation. Innate Immun (2021) 27:503–13. doi: 10.1177/17534259211051364
155
ManikMSinghRK. Role of toll-like receptors in modulation of cytokine storm signaling in SARS-CoV-2-induced COVID-19. J Med Virol (2022) 94:869–77. doi: 10.1002/jmv.27405
156
ChangSEFengAMengWApostolidisSA. New-onset IgG autoantibodies in hospitalized patients with COVID-19. Nat Commun (2021) 12(1):5417. doi: 10.1038/s41467-021-25509-3
157
FujinamiRSZurbriggenAPowellHC. Monoclonal antibody defines determinant between theiler's virus and lipid-like structures. J Neuroimmunol (1988) 20:25–32. doi: 10.1016/0165-5728(88)90110-5
158
TsunodaIKuangLQKobayashi-WarrenMFujinamiRS. Central nervous system pathology caused by autoreactive CD8+ T-cell clones following virus infection. J Virol (2005) 79:14640–6. doi: 10.1128/JVI.79.23.14640-14646.2005
159
MyoungJKangHSHouWMengLDal CantoMCKimBS. Epitope-specific CD8+ T cells play a differential pathogenic role in the development of a viral disease model for multiple sclerosis. J Virol (2012) 86:13717–28. doi: 10.1128/JVI.01733-12
160
PatolePSGroneHJSegererSCiubarRBelemezovaEHengerAet al. Viral double-stranded RNA aggravates lupus nephritis through toll-like receptor 3 on glomerular mesangial cells and antigen-presenting cells. J Am Soc Nephrol (2005) 16:1326–38. doi: 10.1681/ASN.2004100820
161
PisitkunPDeaneJADiffilippantonioMJTarasenkoTSatterthwaiteABBollandS. Autoreactive b cell responses to RNA-related antigens due to TLR7 gene duplication. Science (2006) 312:1669–72. doi: 10.1126/science.1124978
162
GreenNMMarshak-RothsteinA. Toll-like receptor driven b cell activation in the induction of systemic autoimmunity. Semin Immunol (2011) 23:106–12. doi: 10.1016/j.smim.2011.01.016
163
MyoungJBahkYlKangHSDal CantoMCKimBS. Anti-capsid immunity level, not viral persistence level, correlates with the progression of theiler's virus-induced demyelinating disease in viral P1-transgenic mice. J Virol (2008) 82:5606–17. doi: 10.1128/JVI.02442-07
164
DrescherKMPeaseLRRodriguezM. Antiviral immune responses modulate the nature of central nervous system (CNS) disease in a murine model of multiple sclerosis. Immunol Rev (1997) 159:177–93. doi: 10.1111/j.1600-065X.1997.tb01015.x
165
AsakuraKMillerDJPeaseLRRodriguezM. Targeting of IgMkappa antibodies to oligodendrocytes promotes CNS remyelination. J Neurosci (1998) 18:7700–8. doi: 10.1523/JNEUROSCI.18-19-07700.1998
166
HirotaKHashimotoMYoshitomiHTanakaSNomuraTYamaguchiTet al. T Cell self-reactivity forms a cytokine milieu for spontaneous development of IL-17+ Th cells that cause autoimmune arthritis. J Exp Med (2007) 204:41–7. doi: 10.1084/jem.20062259
167
Furuzawa-CarballedaJIcaza-ChavezMEAguilar-LeonDUribe-UribeNNunez-PompaMCTrigos-DiazAet al. Is the sars-CoV-2 virus a possible trigger agent for the development of achalasia? Neurogastroenterol Motil (2023) 35(3):e14502. doi: 10.1101/2022.09.19.22280068
168
CalzasciaTPellegriniMLinAGarzaKMElfordARShahinianAet al. CD4 T cells, lymphopenia, and IL-7 in a multistep pathway to autoimmunity. Proc Natl Acad Sci USA (2008) 105:2999–3004. doi: 10.1073/pnas.0712135105
Summary
Keywords
TLRs, chronic viral infection, inflammation, apoptosis, autoimmunity
Citation
Kim BS (2023) Critical role of TLR activation in viral replication, persistence, and pathogenicity of Theiler’s virus. Front. Immunol. 14:1167972. doi: 10.3389/fimmu.2023.1167972
Received
17 February 2023
Accepted
11 April 2023
Published
20 April 2023
Volume
14 - 2023
Edited by
Oliver Planz, University of Tübingen, Germany
Reviewed by
Sam Basta, Queen’s University, Canada; Karen Bohmwald, Pontificia Universidad Católica de Chile, Chile
Updates
Copyright
© 2023 Kim.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Byung S. Kim, bskim@northwestern.edu
This article was submitted to Molecular Innate Immunity, a section of the journal Frontiers in Immunology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.